Drugs / GSK4527226
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07105709 | Aug 2025 → Sep 2028 expected | Alzheimer disease | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 2 | NCT06079190 | Oct 2023 → Sep 2026 overdue | Alzheimer disease | GlaxoSmithKline | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK4527226 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07105709 ↗ |
| Known as | AL101 | “Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease” NCT06079190 ↗ |
| Route | Intravenous | “GSK4527226 [AL101] Intravenous Infusion Compared With Placebo” NCT06079190 ↗ |